Skip to main content

Recombinant Human CD99-L2 Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 5185-CD

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
5185-CD-050

Key Product Details

Source

CHO

Accession #

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Binding Activity

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived human CD99-L2 protein
Human CD99-L2
(Val20 - Ala188)
Accession #NP_113650
IEGRMD Human IgG1
(Pro100 - Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<1.0 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Val20

Predicted Molecular Mass

44.5 kDa (monomer)

SDS-PAGE

65-75 kDa, reducing conditions

Activity

Measured by its ability to bind biotinylated rmCD99-L2 in a functional ELISA.

Formulation, Preparation and Storage

5185-CD
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution
Reconstitute at 100 μg/mL in sterile PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CD99-L2

CD99 antigen-like 2 (CD99-L2) is a 45 kDa type I transmembrane glycoprotein in the CD99 family of molecules (1 - 3). The major form of human CD99-L2 cDNA encodes a 262 amino acid (aa) precursor with a 25 aa predicted signal sequence, a 160 aa extracellular domain (ECD), a 21 aa transmembrane (TM) segment, and a 56 aa cytoplasmic region (4). This form is called the long form, or isoform E3’-E4’-E3-E4. Other isoforms include the muscle E3-E4, missing aa 45 - 93, and E4, a short form missing aa 45 - 116 (1, 4). E3-E4 and E3’-E3-E4 forms are the major isoforms in mouse and rat, respectively (1). Human forms that diverge at Pro 45 (145 aa precursor) or Met 180 (173 aa precursor) have been sequenced, and would be predicted to lack a TM segment (4, 5). None of the forms contain predicted N-linked glycosylation sites within the ECD, but O-linked glycosylation is likely (1, 2). The ECD of the human CD99-L2 isoform E3-E4 shares 85%, 75% and 70% aa identity with the corresponding forms of mouse, rat, and bovine CD99-L2, respectively. The human CD99 and CD99-L2 ECDs share only about 35% aa identity, but both contain three conserved acidic motifs and are thought to originate from the same ancestral gene (1, 2). The nearly ubiquitous expression of CD99-L2 is similar to that of CD99. Human CD99-L2 cDNA is detected in most organs, but not in thymus (1). In the mouse, protein is detectable in lung, thymocytes, mouse leukocytes and vascular endothelial cells (1, 3, 6). The endothelial cell CD99-L2 is reported to mediate cell aggregation and neutrophil or monocyte, but not lymphocyte, extravasation to inflamed tissue in vivo (3, 6).

References

  1. Suh, Y.H. et al. (2003) Gene 307:63.
  2. Park, S.H. et al. (2005) Gene 353:177.
  3. Schenkel, A.R. et al. (2007) Cell Commun. Adhes. 14:227.
  4. Swissprot Accession # Q8TCZ2.
  5. Entrez Accession # EAW99391.
  6. Bixel, G. et al. (2007) Blood 109:5327.

Long Name

CD99 Molecule-like 2

Alternate Names

CD99B, CD99L2, MIC2L1

Entrez Gene IDs

83692 (Human); 171486 (Mouse); 171485 (Rat)

Gene Symbol

CD99L2

Additional CD99-L2 Products

Product Documents for Recombinant Human CD99-L2 Fc Chimera Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human CD99-L2 Fc Chimera Protein, CF

For research use only

Loading...
Loading...
Loading...